4D Molecular Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| 4D Molecular Therapeutics, Inc. | ||
| Date: February 29, 2024 | By: | /s/ David Kirn |
|---|---|---|
| David Kirn, M.D. | ||
| Chief Executive Officer and Director(Duly Authorized Officer and Principal Executive Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.